This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           April 22, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


New genetic tests for breast cancer hold promise
The New York Times
A Silicon Valley start-up with some big-name backers is threatening to upend genetic screening for breast and ovarian cancer by offering a test on a sample of saliva that is so inexpensive that most women could get it. At the same time, the nation’s two largest clinical laboratories, Quest Diagnostics and LabCorp, normally bitter rivals, are joining with French researchers to pool their data to better interpret mutations in the two main breast cancer risk genes, known as BRCA1 and BRCA2. Other companies and laboratories are being invited to join the effort, called BRCA Share.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

BRCA testing needed for all women with ovarian cancer: Canadian study
CBC News
Every woman who contracts ovarian cancer should be tested for the genes that cause it, regardless of family history, says the head of a cancer study from McGill University in Montreal. Ovarian cancer is not always hereditary. However, the study has concluded it would be better if women who get the disease be tested for the BRCA1 and BRCA2 genetic mutations in order to protect future generations of their family.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Understanding Ovarian Cancer video/booklet available in SGO store
First introduced at the SGO Annual Meeting in Chicago last month, SGO’s Understanding Ovarian Cancer DVD and companion booklet are now available through the SGO Store in packs of 10 for distribution to patients in physicians’ offices.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.


Medical societies answer critics of SGR repeal
Medscape (Free login required)
Organized medicine is both applauding Congressional repeal of Medicare's sustainable growth rate (SGR) formula for physician reimbursement and defending the new payment system in its place. The defense boils down to this: The new scheme may not be perfect, but it's better than the alternative. And Congress can be persuaded to improve it.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

CMS proposes coverage for joint Pap smear and HPV tests
Modern Healthcare
Under a proposed national coverage decision, Medicare would pay for women to get a joint Pap smear and human papillomavirus test every five years to screen for cervical cancer. “Based on a systematic review of the evidence, we propose that HPV and Pap smear co-testing in Medicare beneficiaries using an FDA-approved test is reasonable and necessary for the prevention or early detection of illness or disability and appropriate for Medicare beneficiaries,” the CMS said in its proposed coverage notice.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Geoffrey Forneret at 469-420-2629.


By 2020, the most common HPV-related cancer will affect men
The Huffington Post
While currently recommended for both boys and girls, the HPV vaccine was initially marketed — and is still thought of — as a way to protect young women and girls from cervical, vaginal and vulvar cancer. Boys, it's been commonly thought, should be vaccinated primarily to benefit herd immunity and any future female partners. But a new analysis published in Cancer from researchers at the Princess Margaret Cancer Center in Toronto, Canada, points out that boys who get the vaccine receive important protection as well, not only against genital warts, but against HPV strains that cause oropharyngeal (mouth and throat) cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


US panel 'clarifies' mammogram advice
NBC News
A committee that's been attacked for its controversial mammogram recommendations for half a decade clarified that advice recently, saying they have been misunderstood. The panel says women in their 40s can get mammograms every year if they want to, but said it really needs to be up to a woman to decide if she wants to risk the anxiety of getting a false positive result — one showing a breast lump that turns out not to be cancer, after all.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Visit the SGO Women's Cancer News archive page.


Adding a dual mTOR inhibitor to chemotherapy may benefit some ovarian cancer patients
Health Canal
Combining the investigational mTOR inhibitor AZD2014 with the chemotherapy paclitaxel showed better outcome than when the drugs were tested individually in preclinical studies of cancer models, and a phase I clinical trial of this combination in patients with advanced ovarian cancer and non-small cell lung cancer (NSCLC) showed clinical benefit in some, according to data presented at the AACR Annual Meeting 2015.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

April 15, 2015
April 8, 2015
April 1, 2015
March 25, 2015

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063